Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update

SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Sath Shukla Became President and...

Related Keywords

United States ,Massachusetts ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Ankit Mahadevia ,Patrick Vink ,Sath Shukla ,Lora Grassilli ,Milind Deshpande ,Ted Jenkins ,National Institute Of Allergy ,National Institutes Of Health ,Spero Therapeutics Inc ,Government Agency Research ,Development Authority ,Department Of The Army ,Warfighter Medical Research Program Under Award No ,Exchange Commission ,Health Affairs ,Nasdaq ,Department Of Health ,Zeno Group ,Human Services ,Biomedical Advanced Research ,Administration For Strategic Preparedness ,Office Of The ,Department Of Defense ,Health Media Relations ,Globenewswire Inc ,Drug Administration ,First Patient ,First Visit ,Shukla Became President ,Chief Executive Officer ,Special Protocol Assessment ,Upcoming Anticipated ,Investigational New Drug ,Chief Financial Officer ,Quarterly Report ,Strategic Preparedness ,Advanced Research ,Assistant Secretary ,Joint Warfighter Medical Research Program ,Infectious Diseases ,Relations Contact ,Investor Relations ,Health Media ,Consolidated Statements ,